

Review of: "[Short Communication] Advisory caution message on retail packaging of Levothyroxine and its significance in the treatment of hypothyroidism"

Hozan Mohammadi¹

¹ Tehran University of Medical Sciences

Potential competing interests: No potential competing interests to declare.

The author brings up this critical concern based on years of clinical experience in the field with patients suffering from Hypothyroidism, its complications, and Levothyroxine therapy side effects. There are some pros and cons.

It is a reasonable logic with a practical helpful solution that can guide physicians not only for prescribing Levothyroxine but also can be generalized to other similar sensitive medications in which precise and delicate dose determination is essential for optimal treatment of patients, enhancing their quality of life and the success of the treatment program.

On the other hand, "Is the inclusion of this treatment recommendation and advisory caution message on retail packaging by the pharmaceutical companies that are the beneficiaries, scientifically reliable and evidenced-based?" and "How it can be possible to solve this issue?".

One solution is the direct collaboration of the Health and Drugs Ministry of each country (such as FDA in USA) with the pharmaceutical companies by presenting defined common guidelines, treatment recommendations, and advisory caution messages to be included on retail packaging for some of these sensitive medications by pharmaceutical companies which requires determining legal criteria and a network of cooperation between government organizations and the private sector.

Another effective solution for physicians to improve the accuracy of the treatment process and follow-up of patients is the simultaneous measurement of TSH and Free-4, which has been shown to be statistically significant in some studies.